Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiehuangjiejing (XHJJ) is a traditional Chinese herbal medicine formulated as granules for oral administration. It is being investigated for the treatment of cough variant asthma (CVA) in children. A randomized, double-blind, placebo-controlled multicenter clinical trial was conducted to evaluate its effectiveness and safety in children aged 4 to 7. The formulation's ingredients include ephedra (mahuang), scorpio (quan xie), Sophorae Flavescentis Radix (kusheng), Semen Armeniacae Amarum (xingren), Ginkgo biloba Linn (baiguo), and Radix Glycyrrhizae (gancao). According to traditional Chinese medicine, it is intended to warm the lungs, dispel wind, relieve coughing, and reduce sputum production. Studies suggest it may reduce inflammatory cells and cytokines like TNF, IL-6, and IL-1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiehuangjiejing.